# Plain RAG on Cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 1 (NOTCH3, OMIM:621295)
model: gemini-3.8-flash   generated: 2026-09-28 20:52

Everything below is what the notebook's RAG cells produce for this disease,
pre-computed so you can read it before repeating the exercise with a chat LLM

## 1. The search
query: `NOTCH3 gene Cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy 1`

[1] **125310 - CEREBRAL ARTERIOPATHY, AUTOSOMAL ...**  
    https://omim.org/entry/125310  
    autosomal dominant cerebral arteriopathy with subcortical infarcts and leukoencephalopathy type 1 (CADASIL1) is caused by heterozygous mutation in the NOTCH3 ...

[2] **A Genetic Cause of Cerebral Small Vessel Disease - PMC - NIH**  
    https://pmc.ncbi.nlm.nih.gov/articles/PMC2851292/  
    by JC Choi · 2010 · Cited by 109 — Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a single-gene disorder of the cerebral small blood ...

[3] **Cerebral autosomal dominant arteriopathy with subcortical ...**  
    https://medlineplus.gov/genetics/condition/cerebral-autosomal-dominant-arteriopathy-with-subcortical-infarcts-and-leukoencephalopathy/  
    NOTCH3 gene mutations lead to the production of an abnormal Notch3 receptor protein that impairs the function and survival of vascular smooth ...

[4] **Cerebral Autosomal Dominant Arteriopathy with ...**  
    https://arupconsult.com/ati/cerebral-autosomal-dominant-arteriopathy-subcortical-infarcts-and-leukoencephalopathy-cadasil  
    It is primarily characterized by subcortical ischemic events, such as transient ischemic attacks (TIAs) and strokes. Age of onset and clinical ...

[5] **Cerebral autosomal dominant arteriopathy with subcortical ...**  
    https://www.neurology.org/doi/10.1212/NXG.0000000000000434  
    by G Xiromerisiou · 2020 · Cited by 33 — CADASIL is an autosomal dominant inherited arteriopathy caused by mutations in the NOTCH3. The NOTCH3 gene encodes a single pass transmembrane protein, with ...

[6] **Role of NOTCH3 Mutations in the Cerebral Small Vessel ...**  
    https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.021560?doi=10.1161/STROKEAHA.118.021560  
    Schematic overview of Notch signaling and NOTCH3 cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mutations.

## 2. The context handed to the model
```
[1] 125310 - CEREBRAL ARTERIOPATHY, AUTOSOMAL ...
https://omim.org/entry/125310
autosomal dominant cerebral arteriopathy with subcortical infarcts and leukoencephalopathy type 1 (CADASIL1) is caused by heterozygous mutation in the NOTCH3 ...

[2] A Genetic Cause of Cerebral Small Vessel Disease - PMC - NIH
https://pmc.ncbi.nlm.nih.gov/articles/PMC2851292/
by JC Choi · 2010 · Cited by 109 — Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) is a single-gene disorder of the cerebral small blood ...

[3] Cerebral autosomal dominant arteriopathy with subcortical ...
https://medlineplus.gov/genetics/condition/cerebral-autosomal-dominant-arteriopathy-with-subcortical-infarcts-and-leukoencephalopathy/
NOTCH3 gene mutations lead to the production of an abnormal Notch3 receptor protein that impairs the function and survival of vascular smooth ...

[4] Cerebral Autosomal Dominant Arteriopathy with ...
https://arupconsult.com/ati/cerebral-autosomal-dominant-arteriopathy-subcortical-infarcts-and-leukoencephalopathy-cadasil
It is primarily characterized by subcortical ischemic events, such as transient ischemic attacks (TIAs) and strokes. Age of onset and clinical ...

[5] Cerebral autosomal dominant arteriopathy with subcortical ...
https://www.neurology.org/doi/10.1212/NXG.0000000000000434
by G Xiromerisiou · 2020 · Cited by 33 — CADASIL is an autosomal dominant inherited arteriopathy caused by mutations in the NOTCH3. The NOTCH3 gene encodes a single pass transmembrane protein, with ...

[6] Role of NOTCH3 Mutations in the Cerebral Small Vessel ...
https://www.ahajournals.org/doi/10.1161/STROKEAHA.118.021560?doi=10.1161/STROKEAHA.118.021560
Schematic overview of Notch signaling and NOTCH3 cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) mutations.
```

## 3. The gene, from the sources

The relation of the *NOTCH3* gene to cerebral arteriopathy, autosomal recessive, with subcortical infarcts and leukoencephalopathy is not covered in the provided sources, which only discuss the autosomal dominant form, CADASIL or CADASIL1 [1, 2]. 

According to the provided sources, the *NOTCH3* gene encodes a single-pass transmembrane protein known as the Notch3 receptor [3, 5]. In the cell, this receptor is involved in Notch signaling and is essential for the function and survival of vascular smooth muscle cells [3, 6]. 

Heterozygous variants in the *NOTCH3* gene cause autosomal dominant cerebral arteriopathy with subcortical infarcts and leukoencephalopathy [1, 5]. These mutations lead to the production of an abnormal Notch3 receptor protein that impairs vascular smooth muscle cell survival and function [3]. Ultimately, this leads to a cerebral small-vessel disorder characterized by subcortical ischemic events, including strokes and transient ischemic attacks [2, 4].

*tokens in 664, out 1611*

## 4. The gene, closed book (no sources; beware hallucinations)

The ***NOTCH3*** gene encodes **Notch receptor 3**, a single-pass transmembrane signaling receptor predominantly expressed in vascular smooth muscle cells (VSMCs) and pericytes. It plays a critical role in vascular development, VSMC differentiation, and vessel wall homeostasis. 

Pathogenic variants in *NOTCH3* primarily cause **CADASIL** (Cerebral Autosomal *Dominant* Arteriopathy with Subcortical Infarcts and Leukoencephalopathy; autosomal *recessive* arteriopathy, or CARASIL, is typically caused by *HTRA1*, though rare biallelic *NOTCH3* cases exist). Pathogenic *NOTCH3* variants are predominantly stereotyped missense mutations altering the number of cysteine residues within the epidermal growth factor (EGF)-like repeats of the extracellular domain (ECD). This disrupts normal disulfide bonding, causing abnormal receptor multimerization, toxic extracellular accumulation as granular osmiophilic material (GOM), VSMC degeneration, and microvascular compromise.

The clinical entity was first recognized in **1977** by Sourander and Wålinder.

**Citation:** Sourander, P., & Wålinder, J. (1977). Hereditary multi-infarct dementia: Morphological and clinical studies of a new disease. *Acta Neuropathologica*, 39(3), 247–254. *(NOTCH3* was subsequently identified as the causative gene by Joutel et al., *Nature*, 1996).*

## 5. Which patient? Three independent rounds, same prompt

### Round 1  (picked: P05)

Based on the provided sources, here is the clinical genetic evaluation:

### 1. Rule-in / Rule-out Assessment for Each Patient

The sources define CADASIL1 as an autosomal dominant arteriopathy of cerebral small blood vessels caused by *NOTCH3* mutations [1, 2, 5], primarily characterized by subcortical ischemic events such as transient ischemic attacks (TIAs) and strokes [4]. Crucially, the sources do **not** describe an autosomal recessive form of *NOTCH3*-related arteriopathy, nor do they provide a complete list of clinical features, age of onset, or diagnostic exclusion criteria [1–6]. 

* **P01:** **Cannot be ruled in or ruled out.** The patient lacks documented strokes or TIAs [4], but the sources do not provide exclusion criteria or state whether these non-neurological features can occur [1–6].
* **P02:** **Cannot be ruled in or ruled out.** Subependymal nodules and neurological deficits are listed, but the sources do not provide information on these signs regarding *NOTCH3* [1–6].
* **P03:** **Cannot be ruled in or ruled out.** Cerebral atrophy is present, but the sources do not establish whether atrophy alone without documented subcortical ischemic events/strokes confirms or excludes the diagnosis [1–6].
* **P04:** **Cannot be ruled in or ruled out.** Cerebellar atrophy and thin corpus callosum are present, but the sources do not define whether these brain findings are associated with or exclude *NOTCH3* arteriopathy [1–6].
* **P05:** **Cannot be definitively ruled in or ruled out.** P05 exhibits cerebrovascular and white matter involvement ("Intracranial hemorrhage" and "Focal white matter lesions"), which partially aligns with a cerebral small blood vessel arteriopathy [2, 4]. However, the sources specify subcortical ischemic events (strokes and TIAs) rather than hemorrhage [4], and they do not provide syndromic or congenital criteria to confirm this diagnosis [1–6].
* **P06:** **Cannot be ruled in or ruled out.** Presents with severe encephalopathy and seizures, but the sources do not discuss these features or provide exclusion criteria [1–6].
* **P07:** **Cannot be ruled in or ruled out.** Neurodevelopmental and systemic features are present, but the sources give no basis to evaluate these against *NOTCH3* disease [1–6].
* **P08:** **Cannot be ruled in or ruled out.** Presents with dysmorphic and skeletal features; the sources provide no data linking or excluding these from *NOTCH3* disease [1–6].
* **P09:** **Cannot be ruled in or ruled out.** Craniofacial and neurodevelopmental features are described, but the sources do not provide criteria to evaluate them [1–6].
* **P10:** **Cannot be ruled in or ruled out.** Features include severe developmental delay and seizures, which are neither confirmed nor excluded by the sources [1–6].

---

### 2. Single Most Likely Patient and Probability

* **Most Likely Patient:** **P05**
* **Estimated Probability:** **~70%** (among the 10 options, given that exactly one patient is affected).
* **Rationale:** The disorder specifies a cerebral arteriopathy with leukoencephalopathy. Source [2] notes *NOTCH3* causes cerebral small blood vessel disease, and source [4] notes primary characterization by subcortical brain events. P05 is the only patient in the group with documented brain vascular involvement (**intracranial hemorrhage**) and white matter disease (**focal white matter lesions** / **abnormal CNS myelination**). The probability cannot be 100% because the sources do not describe autosomal recessive *NOTCH3* disease, nor do they explicitly list intracranial hemorrhage, seizures, or dysmorphic features [1–6].

---

### 3. Facts Needed to Be Confident (Not in the Sources)

1. **Characterization of Autosomal Recessive *NOTCH3* Disease:** The sources only describe autosomal dominant inheritance for CADASIL1 [1, 5]; they provide zero information on the autosomal recessive phenotype, inheritance, or specific presentation.
2. **Comprehensive Phenotypic Spectrum:** The sources do not provide a detailed clinical feature breakdown, age of onset, or MRI/neuroimaging criteria beyond mentioning subcortical ischemic events, TIAs, and strokes [4].
3. **Genetic Testing Data:** Direct molecular confirmation (e.g., identification of homozygous or compound heterozygous pathogenic variants in *NOTCH3*) for the candidates [1, 3, 5].
4. **Complete Neuroimaging for All Patients:** Comprehensive brain MRI data are missing for most patients (such as P01, P06, P08), preventing direct comparison of subcortical infarcts and leukoencephalopathy.

--------------------------------------------------------------------------------

### Round 2  (picked: P05)

Based on the provided sources, here is the clinical genetic evaluation:

### 1. Rule In / Rule Out Evaluation for Each Patient

The sources define CADASIL1 as an autosomal dominant disorder caused by heterozygous mutations in *NOTCH3* [1, 5], affecting cerebral small blood vessels [2] and vascular smooth muscle cells [3], primarily characterized by subcortical ischemic events such as transient ischemic attacks (TIAs) and strokes [4]. The sources provide **no** information regarding an autosomal recessive form of *NOTCH3*-related arteriopathy, nor do they list exclusionary phenotypes, syndromic dysmorphisms, or childhood-onset manifestations. 

* **P01:** **Cannot be ruled in or ruled out.** The sources do not describe or exclude features such as cryptorchidism, joint hypermobility, or developmental delay [1–6].
* **P02:** **Cannot be ruled in or ruled out.** The sources do not evaluate whether congenital diaphragmatic hernia, microcephaly, or subependymal nodules occur in or exclude *NOTCH3* arteriopathy [1–6].
* **P03:** **Cannot be ruled in or ruled out.** Cerebral atrophy is present, but the sources do not discuss cerebral atrophy or dysmorphic facial features [1–6].
* **P04:** **Cannot be ruled in or ruled out.** The sources provide no information regarding microcephaly, cerebellar atrophy, or seizures in relation to *NOTCH3* disease [1–6].
* **P05:** **Cannot be ruled in or ruled out definitively.** P05 exhibits neurovascular and cerebral involvement ("Intracranial hemorrhage", "Focal white matter lesions"), which aligns loosely with cerebral small vessel arteriopathy [2] and subcortical ischemic events [4]. However, the sources do not report whether intracranial hemorrhage, hypsarrhythmia, or congenital anomalies belong to this condition [1–6].
* **P06:** **Cannot be ruled in or ruled out.** The sources do not address epileptic encephalopathy or hyperventilation [1–6].
* **P07:** **Cannot be ruled in or ruled out.** The sources do not mention skeletal, ophthalmologic, or respiratory tract abnormalities [1–6].
* **P08:** **Cannot be ruled in or ruled out.** The sources do not mention bicuspid aortic valve, short stature, or syndactyly [1–6].
* **P09:** **Cannot be ruled in or ruled out.** The sources do not describe craniosynostosis, microcephaly, or pulmonary hypoplasia [1–6].
* **P10:** **Cannot be ruled in or ruled out.** The sources do not discuss severe intellectual disability, EEG abnormalities, or hypotonia [1–6].

---

### 2. Single Most Likely Patient and Probability

* **Most Likely Patient:** **P05**
* **Estimated Probability:** **~70%** (among the candidate pool)

**Reasoning:** 
Source [2] identifies *NOTCH3* arteriopathy as a cerebral small blood vessel disease, and Source [4] characterizes it by ischemic/vascular events affecting the brain. P05 is the only patient in the cohort presenting with explicit cerebral white matter lesions ("Focal white matter lesions") and cerebrovascular compromise ("Intracranial hemorrhage"). However, uncertainty remains high because the provided sources only describe an autosomal dominant condition (CADASIL1) [1, 5], whereas the prompt asks for an autosomal recessive condition, which the sources do not define.

---

### 3. Facts Needed (and Not Provided by the Sources) to Be Confident

1. **Information on an Autosomal Recessive Entity:** The sources only describe autosomal dominant inheritance due to heterozygous *NOTCH3* mutations [1, 5]; they do not state whether an autosomal recessive *NOTCH3* disorder exists or what its clinical spectrum comprises.
2. **Genetic / Molecular Data:** Genotype confirmation (e.g., presence of biallelic vs. heterozygous *NOTCH3* variants) for each patient [1, 5].
3. **Comprehensive Clinical Diagnostic Criteria:** Specific MRI neuroimaging criteria (e.g., leukoencephalopathy distribution, subcortical infarcts vs. hemorrhage) [4] and data on whether pediatric features (e.g., hypsarrhythmia, infantile spasms, dysmorphisms) can occur in this disease.
4. **Exclusionary Criteria:** Explicit information on which clinical signs would definitively eliminate a diagnosis of *NOTCH3*-related cerebral arteriopathy [1–6].

--------------------------------------------------------------------------------

### Round 3  (picked: P05)

Based on the provided sources, here is the clinical genetic assessment:

### 1. Patient Rule-In / Rule-Out Assessment

* **P01:** **Cannot be ruled in or ruled out.** The sources define CADASIL as a disorder of cerebral small blood vessels [2] primarily characterized by subcortical ischemic events (such as TIAs and strokes) [4]. The sources provide no clinical or exclusion criteria regarding the developmental, dysmorphic, or behavioral features listed for P01 [1–6].
* **P02:** **Cannot be ruled in or ruled out.** The sources do not provide data to confirm or exclude congenital anomalies, diaphragmatic hernia, or developmental delay in relation to *NOTCH3* arteriopathy [1–6].
* **P03:** **Cannot be ruled in or ruled out.** Although cerebral atrophy is noted, the sources describe small vessel arteriopathy and ischemic events [2, 4] and do not detail whether craniofacial dysmorphisms or seizures are part of the spectrum or exclusionary [1–6].
* **P04:** **Cannot be ruled in or ruled out.** The sources do not provide sufficient phenotypic depth to evaluate whether these dysmorphic, structural brain, and developmental features are consistent with or exclusionary for the condition [1–6].
* **P05:** **Cannot be definitively ruled in or ruled out.** P05 presents with "Intracranial hemorrhage" and "Focal white matter lesions," which conceptually align with cerebral small blood vessel pathology [2] and strokes/ischemic events [4]. However, the sources provide no diagnostic criteria to rule P05 in definitively, nor do they describe the extensive multisystem and developmental phenotype seen here [1–6].
* **P06:** **Cannot be ruled in or ruled out.** The sources provide no information regarding epileptic encephalopathy or hyperventilation in *NOTCH3* arteriopathy [1–6].
* **P07:** **Cannot be ruled in or ruled out.** The sources do not describe multisystem connective, ocular, or skeletal phenotypes, nor do they provide criteria to exclude them [1–6].
* **P08:** **Cannot be ruled in or ruled out.** Congenital cardiac and skeletal features are not described in the sources, nor are they explicitly stated to exclude the condition [1–6].
* **P09:** **Cannot be ruled in or ruled out.** Craniosynostosis and severe syndromic features are neither detailed nor excluded by the sources [1–6].
* **P10:** **Cannot be ruled in or ruled out.** The sources provide no phenotypic data regarding severe non-verbal developmental delay, macrotia, or EEG abnormalities [1–6].

---

### 2. Single Most Likely Patient and Probability

* **Most Likely Patient:** **P05**
* **Estimated Probability:** **~65%**
* **Reasoning:** CADASIL is defined as a cerebral small vessel disorder [2] characterized by subcortical ischemic events/strokes [4]. Among all 10 profiles, P05 is the only patient who has documented cerebrovascular and cerebral white matter pathology (**"Intracranial hemorrhage"** and **"Focal white matter lesions"**). However, the probability cannot be higher because the sources lack detailed clinical criteria, age-of-onset data [4], and phenotype descriptions for recessive *NOTCH3* disease.

---

### 3. Facts Needed (and Not Provided by the Sources) to Be Confident

1. **Phenotypic description of the recessive entity:** The sources exclusively describe an *autosomal dominant* disorder (CADASIL1) caused by heterozygous *NOTCH3* mutations [1, 2, 5]. The sources provide zero information regarding an *autosomal recessive* *NOTCH3* disorder.
2. **Detailed clinical and neuroimaging criteria:** The sources mention "subcortical ischemic events, such as transient ischemic attacks (TIAs) and strokes" [4] and small vessel disease [2], but do not describe specific neuroimaging patterns, leukoencephalopathy distribution, or whether focal white matter lesions and intracranial hemorrhage meet diagnostic criteria [1–6].
3. **Age of onset and pediatric/developmental manifestations:** Source [4] notes that "[a]ge of onset and clinical [characteristics]..." exist, but provides no actual age cutoffs or details on whether early-onset developmental delay, dysmorphic features, or infantile spasms/seizures occur.
4. **Exclusion criteria:** The sources provide no negative criteria to rule out the developmental syndromes represented in P01–P04 and P06–P10 [1–6].
5. **Molecular genetic confirmation:** Direct genetic evidence showing pathogenic biallelic *NOTCH3* mutations in the patient [1, 3, 5].

--------------------------------------------------------------------------------

picks across rounds: ['P05', 'P05', 'P05']
